Let-7a-5p, miR-100-5p, miR-101-3p, and miR-199a-3p Hyperexpression as Potential Predictive Biomarkers in Early Breast Cancer Patients

Background: The aim of this study is to identify miRNAs able to predict the outcomes in breast cancer patients after neoadjuvant chemotherapy (NAC). Patients and methods: We retrospectively analyzed 24 patients receiving NAC and not reaching pathologic complete response (pCR). miRNAs were analyzed u...

Full description

Bibliographic Details
Main Authors: Paola Fuso, Mariantonietta Di Salvatore, Concetta Santonocito, Donatella Guarino, Chiara Autilio, Antonino Mulè, Damiano Arciuolo, Antonina Rinninella, Flavio Mignone, Matteo Ramundo, Brunella Di Stefano, Armando Orlandi, Ettore Capoluongo, Nicola Nicolotti, Gianluca Franceschini, Alejandro Martin Sanchez, Giampaolo Tortora, Giovanni Scambia, Carlo Barone, Alessandra Cassano
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:Journal of Personalized Medicine
Subjects:
Online Access:https://www.mdpi.com/2075-4426/11/8/816
Description
Summary:Background: The aim of this study is to identify miRNAs able to predict the outcomes in breast cancer patients after neoadjuvant chemotherapy (NAC). Patients and methods: We retrospectively analyzed 24 patients receiving NAC and not reaching pathologic complete response (pCR). miRNAs were analyzed using an Illumina Next-Generation-Sequencing (NGS) system. Results: Event-free survival (EFS) and overall survival (OS) were significantly higher in patients with up-regulation of let-7a-5p (EFS <i>p</i> = 0.006; OS <i>p</i> = 0.0001), mirR-100-5p (EFS s <i>p</i> = 0.01; OS <i>p</i> = 0.03), miR-101-3p (EFS <i>p</i> = 0.05; OS <i>p</i> = 0.01), and miR-199a-3p (EFS <i>p</i> = 0.02; OS <i>p</i> = 0.01) in post-NAC samples, independently from breast cancer subtypes. At multivariate analysis, only let-7a-5p was significantly associated with EFS (<i>p</i> = 0.009) and OS (<i>p</i> = 0.0008). Conclusion: Up-regulation of the above miRNAs could represent biomarkers in breast cancer.
ISSN:2075-4426